FDA Approves First Gene Therapy for Severe Hemophilia A
FRIDAY, June 30, 2023 -- The U.S. Food and Drug Administration on Thursday approved a costly single-dose gene therapy for patients with severe hemophilia A, a life-threatening hereditary bleeding disorder.
The treatment is not cheap: Roctavian will...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
More News: Bleeding | Food and Drug Administration (FDA) | Gene Therapy | General Medicine | Genetics | Haemophilia | Hemophilia